Filtered By:
Therapy: Stem Cell Therapy
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1128 results found since Jan 2013.
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
Human CD34 < sup > + < /sup > -derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8 < sup > + < /sup > T cell and NK cell responses in vitro and in vivo
In this study, we aimed to dissect the phenotypic identity of these non-DCs and their potential immune modulatory functions on the potency of cDCs and pDCs in stimulating tumor-reactive CD8+ T and NK cell responses, in order to obtain rationale for clinical translation of our DC-complete vaccine. The non-DC compartment was heterogeneous and comprised of myeloid progenitors and (immature) granulocyte- and monocyte-like cells. Importantly, non-DCs potentiated toll-like receptor-induced DC maturation, as reflected by increased expression of co-stimulatory molecules and enhanced cDC-derived IL-12 and pDC-derived IFN-α product...
Source: Cellular and Molecular Life Sciences : CMLS - September 20, 2023 Category: Cytology Authors: Jesper van Eck van der Sluijs Diede van Ens Jolanda Brummelman Daan Heister Aastha Sareen Lisa Truijen Dorette S van Ingen Schenau Mirjam H M Heemskerk Marieke Griffioen Michel G D Kester Nicolaas P M Schaap Joop H Jansen Anniek B van der Waart Harry Dols Source Type: research
Macrophage colony-stimulating factor as a weapon against cytomegalovirus
EMBO Mol Med. 2023 Sep 12:e18319. doi: 10.15252/emmm.202318319. Online ahead of print.ABSTRACTCytomegalovirus (CMV) infection is one of the severe opportunistic infections faced by severely immunocompromised patients. High viral loads cause tissue-invasive disease and expose to death or various indirect effects. Substantial progress was made in monitoring active infection, and antiviral drugs were developed. However, dose-limiting toxicities and genotypic resistance limit therapeutic efficacy and vaccine development is hampered by the complex biology of the virus. In this issue of EMBO Molecular Medicine, Kandalla et al (2...
Source: Molecular Medicine - September 12, 2023 Category: Molecular Biology Authors: Eric Solary Source Type: research
Stem cell-based therapy for COVID-19
Int Immunopharmacol. 2023 Sep 7;124(Pt A):110890. doi: 10.1016/j.intimp.2023.110890. Online ahead of print.ABSTRACTWhile The World Health Organization (WHO) has announced that COVID-19 is no longer a public health emergency of international concern(PHEIC), the risk of reinfection and new emerging variants still makes it crucial to study and work towards the prevention of COVID-19. Stem cell and stem cell-like derivatives have shown some promising results in clinical trials and preclinical studies as an alternative treatment option for the pulmonary illnesses caused by the COVID-19 and can be used as a potential vaccine. In...
Source: International Immunopharmacology - September 9, 2023 Category: Allergy & Immunology Authors: Xiaomei Chen Bowen Liu Chao Li Yulian Wang Suxia Geng Xin Du Jianyu Weng Peilong Lai Source Type: research
The booster dose of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral and clinical response and serological conversion predictors
Acta Oncol. 2023 Sep 5:1-3. doi: 10.1080/0284186X.2023.2254923. Online ahead of print.NO ABSTRACTPMID:37669166 | DOI:10.1080/0284186X.2023.2254923
Source: Acta Oncologica - September 5, 2023 Category: Cancer & Oncology Authors: Maciej Majcherek Agnieszka Matkowska-Kocjan Donata Szymczak Magdalena Karasek Krzysztof Przeorski Agnieszka Szeremet Aleksandra Kiraga Aneta Milanowska Edwin Kuznik Krzysztof Kujawa Tomasz Wrobel Leszek Szenborn Anna Czyz Source Type: research
Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT
Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.06.075. Online ahead of print.ABSTRACTMeasles outbreaks have raised concerns of fatal infections in immunocompromised patients. Canadian guidelines advise administration of live vaccines, such as measles, mumps, and rubella (MMR), two yearsafter hematopoietic stem cell transplant (HSCT) yet studies have not assessed eligibility based on medication contraindications. We retrospectively reviewed the charts of 72 autologous (auto-HSCT) and 68 allogeneic (allo-HSCT) recipients at the Windsor Regional Cancer Center to determine MMR reactivity and eligibilit...
Source: Vaccine - August 31, 2023 Category: Allergy & Immunology Authors: Gopika Punchhi Rainbow Negus Hammad Saif Sharon Pritchard Olivia Owen Aman Sehmbi Caroline Hamm Source Type: research
Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives
Leuk Res. 2023 Jul 27;133:107365. doi: 10.1016/j.leukres.2023.107365. Online ahead of print.ABSTRACTSecondary immunodeficiency (SID) can occur as a result of multiple factors, including hematological malignancies, hematopoietic stem cell transplantation (HSCT), immunosuppressive treatment, biologics, and anti-inflammatory drugs. SID includes disorders resulting from impairment of both cellular and humoral immunity. This review focuses on the current risk factors, implications, and challenges in managing SID patients with impaired humoral immunity, which includes quantitative (hypogammaglobulinemia) and/or functional antibo...
Source: Cell Research - August 29, 2023 Category: Cytology Authors: Muhlis Cem Ar Riad El Fakih Saule Gabbassova Ahmad Alhuraiji Fady Nasr Ahmad Alsaeed Nilgun Sayinalp Mahmoud Marashi Source Type: research
New and future therapies: Changes in the therapeutic armamentarium for SLE
Best Pract Res Clin Rheumatol. 2023 Aug 24:101865. doi: 10.1016/j.berh.2023.101865. Online ahead of print.ABSTRACTFollowing better understanding of molecular pathways involved in the pathogenesis of Systemic lupus erythematosus (SLE), pharmaceutical companies have been investigating new targeted drugs for SLE. The purpose of this scoping review is to provide an updated view of the most promising targeted therapies currently in clinical development or recently approved for SLE treatment as well as of the most promising potential future therapeutic strategies in SLE. In the past several years, two new drugs have been develop...
Source: Cell Research - August 26, 2023 Category: Cytology Authors: Anca Askanase Leila Khalili Wei Tang Philippe Mertz Marc Scherlinger Eden Sebbag Fran çois Chasset Renaud Felten Laurent Arnaud Source Type: research
